埼玉医科大学 · 医学部 / 医学研究科 · 講師

研究キーワードnon-small cell lung cancer・durvalumab maintenance・nivolumab retreatment・pegylated G-CSF・immune-related adverse events・thoracic oncology

ここは公開データのプレビューです。個別の適合理由、連絡角度、保存機能はログイン後に利用できます。

• Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer
• Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer
• 吸入ステロイドが著効した挿管後気管狭窄の1例
• Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab.

• 公式プロフィール